• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Heart Failure Drug Stirs Controversy

Posted on: Wednesday, 13 July 2005, 18:01 CDT

WEDNESDAY, July 13 (HealthDay News) -- A hard-hitting article in one of the nation's most prestigious medical journals claims the maker of the widely used heart failure drug Natrecor is circumventing concerns over patient safety while watching revenues soar.

One of the country's top cardiologists asserts that Scios Inc., a subsidiary of Johnson & Johnson, continues to aggressively market Natrecor even as the drug comes under increased scrutiny for links to kidney failure and death.

"It's a pattern. We saw it with Vioxx and some of the cox-2 inhibitor drugs, and we're seeing it now with Natrecor," said Dr. Eric Topol, author of the article, which appears in the July 14 issue of the New England Journal of Medicine. "The twist here is that the aggressive marketing is through the medical community. With other drugs, it's direct-to-consumer advertising."

"Other than that, we have the themes of manuscripts published in prestigious journals with key omissions of data, the FDA approving drugs without mandating key trials, and companies aggressively pursuing sales and marketing of their drugs," continued Topol, who is chairman of the department of cardiovascular medicine and chief academic officer at the Cleveland Clinic in Ohio.

Natrecor (nesiritide) was approved by the FDA in 2001 for the treatment of acute, decompensated congestive heart failure, a stage of heart failure characterized by increased severity and long hospital stays. According to the company, it is the first member of a new drug class, human B-type natriuretic, and is manufactured from E. coli bacterium using recombinant DNA technology.

Today, tens of thousands of patients in the United States are receiving weekly or more frequent "tune-ups" with the drug on an outpatient basis, an indication for which the drug is not approved, Topol said. In fact, the drug, which costs about $500 per dose, is now being used 10 times more often in outpatient clinics than in acute hospital settings. This is happening despite troubling safety data and less-than-convincing efficacy, he said.

Sales for Natrecor are projected to be $700 million for 2005, Topol wrote, nearly double what they were last year.

According to Topol, studies have shown that Natrecor contributes to kidney dysfunction, and may even cause death. One trial found that kidney problems were occurring at a rate three times that found in patients taking a placebo. Another trial found a 50 percent increase in the risk of death at 30 days. And when data from three trials was pooled, researchers led by Dr. Jonathan Sackner-Bernstein, a New York cardiologist, found an 81 percent increase in the death rate vs. a placebo.

In his article, Topol says Natrecor was approved on the basis of only one trial in which surrogate outcomes were assessed three hours after patients took the drug.

"It hardly does any better than placebo," said Sackner-Bernstein, associate chief of cardiology and the director of the Heart Failure Program at St. Lukes-Roosevelt Hospital Center, New York City.

He said he had great difficulty getting his data published in any medical journals, although two studies conducted by his team that found problems with Natrecor did eventually appear in Circulation and the Journal of the American Medical Association earlier this year. He also took his data to the company.

"People were much more comfortable assuming this drug was safe," Sackner-Bernstein said. "In many ways, they were acting like the proverbial ostrich with its head in the sand."

But particularly troubling to Topol and others has been the aggressive marketing undertaken by the company even after safety issues had been raised.

According to the article, Scios is encouraging physicians to start their own "infusion centers," which would be billed to Medicare as if they were providing chemotherapy; it has also set up a toll-free telephone hotline for "Natrecor Reimbursement Support" and published a 46-page reimbursement and billing guide that even provides doctors with specific Medicare billing codes.

"If a drug is off-label, the FDA basically takes a blind-eye approach," Topol said. "There's a very fuzzy line about promotion. The company would say we're not promoting the outpatient tune-up. Well, how come they have a hot line, and any doctor can call and set something up? Is that not promoting it? Come on, help me. Where do you draw the line?"

In June, an expert panel convened at Scios' request recommended that the company conduct additional trials to assess the safety and efficacy of Natrecor. The panel also stated that use of the drug should be restricted to patients coming to the hospital with acutely decompensated congestive heart failure.

In a statement released at the time, Dr. Darlene Horton, the company's senior vice president of clinical research and medical affairs, said, "Scios fully agrees that these are areas for which there are not sufficient data to support the use of Natrecor. The company will continue and build upon its efforts to educate physicians regarding appropriate use."

Attempts made by HealthDay to reach Scios officials for comment were unsuccessful.

Back in June, the response was heartening to experts who had been pushing for changes.

"As a set of recommendations, it was very reasonable," Sackner-Bernstein said. "But it's been disappointing to me to see how little impact that statement has had. It was important for about three days."

If Scios was committed to their plan of doing more studies, Sackner-Bernstein added, "I would have expected to hear more from them by now. . . I would think Johnson & Johnson would like to prove to the world that they do care about patients, that they do have ethics, and it's pretty clear to me that it's not their motivation."

The ideal situation, as Sackner-Bernstein sees it, would have been for him and others to go to the company and talk to them (which they did), and for the company and the FDA to have worked out the situation.

"If the system worked, then all this stuff would have been unnecessary, irrelevant," he said.

"The fact that the FDA doesn't have much enforcement capability is a problem," Sackner-Bernstein said. "Then again, where are the ethics? The people involved at Scios and others who knew about this data should be hanging their heads. There's no other way to look at it. What is wrong with everybody that you've got a drug that increases renal dysfunction and death, and costs 50 times as much as a regular treatment, and yet it's given to hundreds of thousands of people?"

More information

The American Heart Association provides a detailed explanation of heart failure.

SOURCES: Eric J. Topol, M.D., chairman, department of cardiovascular medicine, and chief academic officer, Cleveland Clinic, Cleveland; Jonathan Sackner-Bernstein, M.D., associate chief, cardiology, and director, Heart Failure Program, St. Lukes-Roosevelt Hospital Center, New York; July 14, 2005, New England Journal of Medicine; June 13, 2005, Scios Inc. statement~SAFP~~FDA-~~HRTD~

Source: HealthSCOUT

More News in this Category